Overview

Gender

male

Daniel O'Day serves as Chief Operating Officer of Pharmaceuticals at Roche Holding AG. O'Day serves as the Chief Operating Officer of Roche Diagnostics GmbH and Hoffmann-La Roche Ltd. O'Day served as the Chief Executive Officer and President of Roche Molecular Diagnostics at Roche Carolina Inc. and Roche Holding AG. He served as the Chief Operating Officer of Roche Pharma AG since September 1, 2012. O'Day served as the Chief Executive Officer and President of Roche Diagnostics GmbH. O'Day was with Roche for more than 20 years, following positions of increasing responsibility in sales, marketing, and human resources.

He began his career in 1987 at Roche in the U.S. Pharmaceuticals organization in Sales and Marketing. Afterwards, he held various positions in Roche Pharma in Switzerland, Japan, and Denmark. In 2006 O'Day joined Roche Diagnostics and became Head of the Business Area Molecular Diagnostics. On January 1 2010 he was appointed as Chief Operating Officer for Roche's global diagnostics business. He worked 11 years managing international assignments that included life cycle leadership at Roche Pharmaceuticals in Basel, Switzerland; strategic planning and involvement in the Chugai merger in Tokyo, Japan; and, prior to joining the molecular diagnostics unit, served as General Manager of Roche Pharmaceuticals in Denmark. He has been a Director of Chugai Pharmaceutical Co. Ltd. since March 27, 2013. He serves as a Director of Genentech, Inc. and California Healthcare Institute.

O'Day holds an undergraduate degree in Biology from Georgetown University and a Master of Business Administration from Columbia University.